Find the latest Geron Corporation (GERN) stock quote, history, news and other vital information to help you with your stock trading and investing. Check out our GERN stock analysis, current GERN quote, charts, and historical prices for Geron Corp GERN Stock Predictions, Articles, and Geron Corp News . Stock analysis for Geron Corp (GERN:NASDAQ GS) including stock price, stock chart, company news, key statistics, fundamentals and company profile. Get today's Geron Corporation stock price and latest GERN news as well as Geron Carnival Corp, 11.30, 12.95, 11.05, +1.09, +10.68%, 183.58M, 15:59:59. Geron Corp is a clinical stage biopharmaceutical company. Its focus is the development of a telomerase inhibitor, imetelstat, in hematologic myeloid
GERN - Geron Corp Stock Price History - Barchart.com
Mar 10, 2020 The Stock rose vividly during the last session to $1.06 after opening rate of $0.99 while the lowest price it went was recorded $0.98 before closing GERN - Geron Corp Stock quote - CNNMoney.com EPS forecast (this quarter)-$0.12: Annual revenue (last year) $460.0K: Annual profit (last year)-$68.5M: Net profit margin-14,901.74% Geron Stock Forecast: up to 1.830 USD! - GERN Stock Price ...
Nov 10, 2019 · Geron Corp. analyst estimates by MarketWatch. View GERN revenue estimates and earnings estimates, as well as analyst recommendations. Real-time last sale data for U.S. stock …
Investing ideas, stock information, fundamental analysis, technical analysis on GERON CORP ($GERN) from Singapore's largest stock investing community. Mar 9, 2020 Geron Corporation (NASDAQ: GERN) is -25.00% lower on its value in If we measure the stock's price variations over the week and the month, The company's main competitors (and peers) include CTI BioPharma Corp. View recent trades and share price information for Geron Corp Com Stk USD0. 001. Dividend information for this stock is not available. Data policy - All Profile for Geron Corporation (GERN) Stock Ticker for GERN Geron $GERN Price Target Cut to $3.00 by Analysts at BTIG Research https://t.co/hWyYSiWmXo . April 5th $GERN: New Insider Filing on GERON CORP's Director ROBERT J. Mar 9, 2020 The one-year Geron Corporation stock forecast points to a potential upside of 72.8. The average equity rating for GERN stock is currently 1.80, How has Geron's share price performed over time and what events caused price Introducing Geron (NASDAQ:GERN), The Stock That Slid 58% In The Last
GERN | Geron Corp. Analyst Estimates | MarketWatch
Geron Corp, GERN:NSQ forecasts - FT.com All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions. Geron Corporation Stock Forecast, "GERN" Stock Predictons ... Geron Corporation Stock Price Forecast, "GERN" Predictons for2020 Business and Financial News - CNN Money
The one-year Geron Corporation stock forecast points to a potential upside of 72.8. The average equity rating for GERN stock is currently 1.80, trading closer to a bullish pattern in the stock market. The market cap for the stock reached $225.70 million, with 221.27 million shares outstanding and 198.97 million shares in the current float.
Sep 04, 2018 · Bullish signals on multiple time frames are supporting the notion that Geron Corporation (NASDAQ:GERN) is likely to appreciate and head toward higher GERN stock prices. PCTY Stock Forecast
Imetelstat | Myelofibrosis | Myelodysplastic Syndrome | Geron Geron is a clinical stage biopharmaceutical company focused on the development of a telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. Geron Corporation (GERN) Stock Analysis & News | Seeking Alpha Get breaking news and analysis on Geron Corporation (GERN) stock, price quote and chart, trading and investing tools. Geron Corporation - Investors Geron is a late-stage clinical biopharmaceutical company focused on the development and potential commercialization of our first-in-class telomerase inhibitor, imetelstat, in hematologic myeloid malignancies.Early clinical data suggest imetelstat may have disease-modifying activity through the suppression of malignant progenitor cell clone proliferation, which allows potential recovery of GERN Stock Quote of Geron Corp - InvestorPlace